GlassScriptPhysician profile
Changchun A Wu
NPI 1265642821
$6,466.58
in general payments reported to CMS, 2019-2025
46 companies · $1,007 in 2025
The $1,007 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $236 · 2021: $1,319 · 2022: $1,105 · 2023: $1,038 · 2024: $1,488 · 2025: $1,007.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,508 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,507.71 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,210.17 | 2019-2025 | Ubrelvy, Linzess, Qulipta |
| Novo Nordisk INC | $890.16 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $632.33 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $426.63 | 2023-2025 | |
| Biohaven Pharmaceuticals, INC. | $274.00 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $226.84 | 2022 | |
| Impel Pharmaceuticals INC. | $161.07 | 2022-2023 | Trudhesa |
| Glaxosmithkline, LLC. | $146.01 | 2020-2025 | Trelegy Ellipta, Shingrix |
| Boston Scientific Corporation | $143.45 | 2021-2024 | Wavewriter Alpha Prime 16 |
| Abbott Laboratories | $142.03 | 2022 | |
| Azurity Pharmaceuticals, INC. | $137.90 | 2023-2025 | Horizant, Edarbyclor, Horizant |
| Calliditas Therapeutics US INC. | $132.50 | 2023 | Tarpeyo |
| Neurocrine Biosciences, INC. | $131.68 | 2024 | Ingrezza |
| Jazz Pharmaceuticals INC. | $130.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $123.49 | 2023 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $119.56 | 2022 | |
| Eisai INC. | $119.08 | 2024 | |
| Harmony Biosciences LLC | $116.93 | 2022 | |
| Gilead Sciences, INC. | $114.43 | 2025 | Vemlidy |
| Emd Serono, INC. | $112.36 | 2021 | |
| Silk Road Medical, INC. | $106.72 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Lilly USA, LLC | $88.30 | 2021-2024 | Mounjaro, Emgality |
| Axsome Therapeutics, INC. | $81.98 | 2025 | Symbravo |
| Astellas Pharma US INC | $78.52 | 2023-2025 | Veozah |
| Teva Pharmaceuticals USA, INC. | $61.11 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.88 | 2023 | Tradjenta, Synjardy |
| Impel Pharmaceuticals LLC | $46.18 | 2024-2025 | Trudhesa |
| Shield Therapeutics INC | $45.57 | 2024-2025 | |
| Amgen INC. | $42.83 | 2022-2024 | Prolia, Evenity |
| Scilex Pharmaceuticals INC. | $41.52 | 2024-2025 | |
| Currax Pharmaceuticals LLC | $40.07 | 2022-2023 | Nexletol |
| Ibsa Pharma INC. | $36.14 | 2023 | Tirosint, Licart |
| Esperion Therapeutics, INC. | $29.71 | 2025 | Nexletol |
| Arbor Pharmaceuticals, INC. | $28.32 | 2020-2022 | |
| Corcept Therapeutics | $22.44 | 2024 | Korlym |
| Dexcom, INC. | $21.30 | 2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $19.84 | 2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $19.19 | 2023 | Belsomra, Steglatro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.89 | 2024 | Xifaxan, Trulance |
| Horizon Therapeutics Plc | $18.57 | 2023 | Krystexxa |
| Amneal Pharmaceuticals LLC | $18.04 | 2025 | Brekiya |
| Allergan, INC. | $17.54 | 2020 | |
| Collegium Pharmaceutical, INC. | $16.76 | 2022 | |
| Phadia US INC. | $13.34 | 2024 | Immunocap |
| Almatica Pharma LLC | $11.08 | 2021 | |
| Forte Bio-Pharma LLC | $2.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Changchun Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.